AHAA Weekly Policy Report: December 31st, 2025

Year-End Regulatory Activity Across Cannabis, Hemp, and Agricultural Policy

The final full week of 2025 brings significant regulatory developments affecting the cannabis and hemp industries nationwide. AHAA tracked 16 policy items across 9 jurisdictions, with states finalizing key regulations before year-end and federal executive action on medical marijuana research. Wyoming implements comprehensive hemp production rules, Michigan advances marijuana retailer licensing caps, and New Jersey creates a federal-aligned framework for hemp-derived cannabinoid products.

Key Highlights

Federal Level:

• Presidential Executive Order on Medical Marijuana Research

Hemp-derived Product Market:

• Federal executive order expands medical marijuana and CBD research efforts

• Wyoming finalizes hemp production and processing regulations

• Alabama Restricts Hemp Product Sales to Pharmacies

Medical/Recreational Product Markets:

• Michigan introduces cannabis retailer license caps tied to population density

• New Jersey aligns hemp product regulations with federal standards

• Florida establishes harvest failure protocols for medical marijuana treatment centers

• Florida Veterans Medical Marijuana Fee Reduction

• Massachusetts Modernizes Cannabis Control Structure

• New Jersey Cannabis Regulatory Commission Restructuring

• Ohio Comprehensive Cannabis Reform (Awaiting Governor)

• District of Columbia Medical Cannabis & Streatery Program

Federal Executive Action

Presidential Executive Order on Medical Marijuana Research

Document: Presidential Document 2025-23846 (Executive Order 14370)

The White House issues an executive order directing expanded research and improved access to medical marijuana and cannabidiol (CBD). The order emphasizes FDA findings supporting marijuana's medical use for chronic pain, chemotherapy-induced nausea, and anorexia associated with wasting diseases. Key provisions include support for HHS recommendations to reschedule marijuana from Schedule I to Schedule III under the Controlled Substances Act and addressing the regulatory framework for hemp-derived cannabinoid products currently outside controlled substance classification but subject to FDA oversight. The order notes that nearly 15% of seniors use CBD, with many reporting improvements in chronic pain management, highlighting the gap between widespread use and current medical knowledge regarding risks and benefits.

Read Executive Order 14370

Hemp-Derived Cannabinoid Product Regulatory Updates

Wyoming Establishes Comprehensive Hemp Framework

Regulation: Chapter 61: Rules Pertaining To Hemp (Emergency Notice) - Effective December 23, 2025

Wyoming Department of Agriculture finalizes emergency regulations governing hemp production and processing statewide. Key provisions include:

Licensing Requirements:

• License fees determined by application type

• Criminal History Reports required for all Key Participants

• Licenses valid for calendar year of approval, expiring December 31

• 2025 licensees may extend expiration to April 15, 2026, by submitting renewal documents before year-end

Processing & Storage Standards:

• Each batch must be tested by a Certified Laboratory to ensure THC compliance

• Detailed record-keeping required for inspection

• Non-compliant cannabis must be disposed of per outlined methods

• Storage regulations govern hemp handling and security

Compliance & Enforcement:

• Department authority to deny or revoke licenses based on violations

• Licensees responsible for non-compliant product disposal costs

• Corrective action plans required for regulatory violations

• Appeal process available with specified timelines

These regulations impose rigorous requirements on hemp processors, potentially leading to increased operational costs but establishing clear compliance standards for Wyoming's hemp industry.

Read Wyoming Hemp Regulations

New Jersey Creates Federal-Aligned Hemp Framework

Bills: NJ A 6295 | NJ S 4509 (Passed Both Houses 57-7-6)

New Jersey enacts comprehensive legislation creating a regulatory framework for hemp-derived cannabinoid products aligned with federal standards. S 4509 passed the Assembly with substitution for A 6295 on December 22, 2025, repealing previous intoxicating hemp laws.

Key Provisions:

Licensing Categories:

• Cannabis cultivators, manufacturers, wholesalers, retailers, delivery services, and testing facilities

• Each category requires compliance with specific health and safety standards

• Diversity promotion for businesses owned by socially and economically disadvantaged community residents

• Clear definitions for hemp-related terms and regulatory requirements

Financial Framework:

• Revenue allocation to special fund for social equity investments and underage prevention programs

• Licensing fees and cannabis sales taxes generate state revenue

• Support for educational initiatives and economic development in designated impact zones

• Job creation opportunities within regulated cannabis and hemp industries

Operational Requirements:

• Strict advertising restrictions preventing minor-targeted marketing

• Security protocols for employee and consumer safety

• Comprehensive record-keeping and reporting mandates

• Testing and labeling compliance for all hemp-derived products

• Market opportunities for compliant agriculture, retail, and manufacturing businesses

Bill Forecast (S 4509): 95% Assembly floor vote, 64% Assembly passage | 95% Senate floor vote, 76% Senate passage

Read NJ A 6295 | Read NJ S 4509

Alabama Restricts Hemp Product Sales to Pharmacies

Bill: AL SB 1 (Read First Time - January 13, 2026)

Alabama introduces legislation restricting sales of nonpsychoactive consumable hemp products to licensed pharmacies certified by the Alabama State Board of Pharmacy. The bill also classifies psychoactive hemp derivatives as Schedule I controlled substances. First reading occurred January 13, 2026, with referral to Senate Committee on Healthcare.

Key Provisions:

Distribution Restrictions:

• Consumable hemp product sales limited to licensed pharmacies only

• Products must derive from hemp cultivated within Alabama

• Laboratory testing and certificate of analysis required prior to sale

• Seed-to-sale tracking system for cultivation through retail

Controlled Substance Scheduling:

• Psychoactive hemp derivatives classified as Schedule I drugs

• Alabama Department of Forensic Sciences determines synthetic controlled substance analogue qualifications

• Notifications sent to Alabama Department of Public Health for scheduling

• Exceptions for substances with approved new drug applications or investigational use exemptions

Industry Impact:

• Increased operational costs for testing and compliance

• Market access limited to pharmacy-licensed retailers

• Enhanced consumer protection through rigorous oversight

• Potential market contraction for non-pharmacy hemp retailers

Effective Date: Upon enactment (prior consumable hemp distribution and sale restrictions repealed)

Bill Forecast: 30% House floor vote likelihood | 29% Senate floor vote likelihood

Read AL SB 1

Cannabis & Marijuana Regulatory Updates

Cannabis Licensing & Market Structure

Michigan Marijuana Retailer License Caps

Bills: MI HB 5442 | MI HB 5443 (Tie Bar Package)

Michigan advances legislation establishing population-based limits on marijuana retailer licenses effective January 1, 2026. The cannabis regulatory agency will cap retailer licenses at one per 5,000 residents in each municipality, although this limitation does not apply to license renewals or transfers of existing licenses.

Key Provisions:

Agency Responsibilities:

• Oversee commercial production and distribution oversight

• Process license applications for retailers, processors, and growers

• Conduct compliance inspections and public engagement

• Establish health and safety standards including testing and labeling requirements

• Mandate warnings on packaging for pregnant or breastfeeding women

• Collect licensure fees and violation fines

Zoning & Ownership Restrictions:

• Marijuana establishments prohibited in exclusively residential zones

• 1,000-foot buffer from schools (reducible by municipal ordinance)

• Ownership limitations prevent simultaneous interests in multiple business types

• Specific caps on number of growers and microbusinesses per owner

Application Priority:

• Initial applications limited to Michigan residents or medical marihuana facilities licensing act holders

• Focus on promoting participation from communities disproportionately affected by prohibition

• Background checks required for all applicants

Resort District Provisions (HB 5443):

• Municipalities may apply for resort district designation

• Additional retailer licenses available for qualifying tourism-based areas

• Denied applicants in resort districts may seek exemptions with adequate capital demonstration

• Applicant information confidential under Freedom of Information Act exemption

Bill Forecast: 35% House floor vote likelihood, 25% House passage | 42% Senate floor vote, 49% Senate passage

Read MI HB 5442 | Read MI HB 5443

Michigan Medical Marijuana Provisioning Center Limits

Bill: MI HB 5444 (Tie Bar with HB 5442, 5443, 5441)

Companion legislation applies similar population-based licensing caps to medical marijuana provisioning centers beginning January 1, 2026. The cannabis regulatory agency will limit new provisioning center licenses to one per 5,000 residents per municipality, with exemptions for resort district applicants demonstrating need for additional centers.

Regulatory Framework:

• Licensing for growers, processors, provisioning centers, secure transporters, and safety compliance facilities

• Stringent applicant criteria requiring extensive personal and business information

• Background checks and fingerprinting for financial and criminal history compliance

• Annual license renewals contingent upon timely applications and fee payment

• Public meeting records and annual reporting to governor and legislature

Bill Forecast: 35% House floor vote likelihood, 25% House passage | 42% Senate floor vote, 49% Senate passage

Read MI HB 5444

Florida Harvest Failure & Wholesale Transfer Protocols

Regulation: 64ER25-4 MMTC Harvest Failures And Wholesale Transfers - Effective December 22, 2025

Florida Department of Health establishes emergency rules governing wholesale marijuana transfers following harvest failures at medical marijuana treatment centers (MMTCs). The regulation addresses losses from natural disasters, equipment malfunctions, pest infestations, contamination, flooding, or fire.

Certification Requirements:

• MMTCs must obtain Department certification for wholesale transfers following harvest failures

• Completed form and supporting documentation due within 30 days of incident

• One harvest failure certification per cultivation facility per twelve months (natural disaster exceptions apply)

• Active dispensing requirement: eight consecutive weeks of marijuana distribution to qualified patients prior to request

Transfer Procedures:

• Wholesale transfer request form submission within 30 days of certification

• Documentation in MMTC's internal seed-to-sale tracking system

• Acquiring MMTCs must comply with all testing and labeling standards

• Transfers approved before December 22, 2025, must complete within 90 days

Financial Implications:

• MMTCs responsible for managing financial losses

• Disposal costs for non-compliant products borne by licensees

• Certification and transfer process administrative costs

Read Florida MMTC Regulations

Florida Veterans Medical Marijuana Fee Reduction

Bill: FL HB 887 (Filed for 2026 Regular Session)

Florida proposes reducing medical marijuana registry identification card fees for qualified veterans from standard rates to $15 for issuance, replacement, or renewal. Effective July 1, 2026.

Eligibility Documentation:

• DD-214 discharge form

• Department of Veterans Affairs identification card

• Uniformed Services identification card with retired status indicator

• Florida driver license with veteran designation

Policy Objectives:

• Reduce financial barriers for veteran patients

• Enhance medical marijuana program participation among veteran population

• Recognize military service through healthcare cost reduction

Bill Forecast: 41% floor vote likelihood in both House and Senate chambers

Read FL HB 887

New Jersey Adds Sickle Cell Anemia as Qualifying Condition

Bill: NJ A 913 (Passed Both Houses 37-0)

New Jersey authorizes medical cannabis for treating sickle cell anemia, expanding qualifying medical conditions. The legislation passed the Senate unanimously on December 22, 2025, following earlier Assembly approval.

Industry Impact:

• Increased patient eligibility pool

• Higher demand for medical cannabis products

• Revenue growth for cultivators, manufacturers, and dispensaries

• Academic medical center research opportunities on cannabis applications

Bill Forecast: 74% Assembly floor vote, 72% Assembly passage | 88% Senate floor vote, 87% Senate passage

Read NJ A 913

Massachusetts Modernizes Cannabis Control Structure

Bill: MA H 4206 (Conference Committee Appointed December 24, 2025)

Massachusetts advances comprehensive cannabis law modernization establishing a three-member Cannabis Control Commission with enhanced oversight authority. Conference committee appointed to reconcile House and Senate versions.

Commission Structure:

• Three appointed commissioners overseeing cannabis regulatory compliance

• Social equity promotion within industry operations

• Medical marijuana establishment licensing and regulation

• Consumable CBD product sale management

Advisory Framework:

• Cannabis advisory board with stakeholder representation from cultivation, manufacturing, retail, social justice, and public health sectors

• Independent testing laboratory requirements for product safety compliance

• Code of ethics preventing commissioner conflicts of interest

Regulatory Oversight:

• Hemp beverage and consumable CBD product licensing for manufacturers and retailers

• Product registration processes and financial operations oversight

• Compliance measures including enforcement actions and penalties

• Ongoing studies assessing cannabis use financial impacts on healthcare system

Bill Forecast: 95% House floor vote, 64% House passage | 95% Senate floor vote, 85% Senate passage

Read MA H 4206

New Jersey Cannabis Regulatory Commission Restructuring

Bill: NJ S 4847 (Senate Amendment December 22, 2025)

New Jersey reforms Cannabis Regulatory Commission membership and marketplace regulations. Senate amended the bill by voice vote on December 22, 2025.

Commission Reforms:

• Five-member commission appointed by Governor, Senate President, and Assembly Speaker

• Members required to have relevant experience in law, business, public health, or social justice

• Strict Code of Ethics prohibiting conflicts of interest

• Employment restrictions for commission members and staff

Licensing Framework:

• Detailed operating plans required from all license applicants

• Community impact and social responsibility considerations

• Priority for residents of designated "impact zones"

• Reserved license portion for microbusinesses

• Initial 24-month limitations on cultivator, manufacturer, wholesaler, distributor, and retailer licenses (alternative treatment center exemptions)

Municipal Authority:

• Local governments empowered to regulate establishment numbers and locations

• Existing medical cannabis dispensaries may apply for retail licenses without additional municipal approval if co-located with compliant dispensaries

Cannabis Delivery Services:

• Permitted under specific conditions including municipal approval

• Certification requirements for individuals handling, transporting, and delivering cannabis

Social Equity Provisions:

• Support for minority, women-owned, and disabled-veteran businesses

• Significant investor interest allowances in Class 5 cannabis retailers

• Non-discrimination protections for employees' lawful cannabis use (employers retain drug testing rights under specific circumstances)

Bill Forecast: 80% Assembly floor vote, 72% Assembly passage | 78% Senate floor vote, 85% Senate passage

Read NJ S 4847

Ohio Comprehensive Cannabis Reform (Awaiting Governor)

Adult-Use and Medical Marijuana Comprehensive Revisions

Bill: OH SB 56 (Line Item Veto Receipt - December 23, 2025)

Ohio's comprehensive marijuana legislation revises both medical and adult-use cannabis laws while levying new marijuana taxes. The bill received line item veto receipt on December 23, 2025, and awaits final gubernatorial action.

Division of Cannabis Control:

• New division within Department of Commerce

• Licensing oversight for cultivators, processors, and retail dispensaries

• Local zoning law compliance enforcement

• Age restriction compliance (21+)

Testing & Product Safety:

• Drinkable cannabinoid product testing requirements

• Safety and quality assurance protocols

• Student-athlete ethical considerations addressed

Legal Reforms:

• Expungement process for certain drug-related offenses

• Clear guidelines for medical and adult-use marijuana possession and distribution

• Licensed dispensary requirements for consumer verification and product labeling

Housing & Employment:

• Housing rights protections for registered patients

• Employer regulations regarding marijuana use and workplace policies

• Financial institution guidance for servicing licensed marijuana businesses

Local Government Authority:

• Municipal control over licensed business numbers

• Zoning and location regulations

• Host Community Cannabis Payments distribution

Revenue Framework:

• Excise tax on adult-use marijuana sales

• Community fund support from tax revenue

• Financial allocation for municipalities and regulatory operations

Bill Forecast: 62% House floor vote, 38% House passage | 87% Senate floor vote, 84% Senate passage

Read OH SB 56

District of Columbia Medical Cannabis & Streatery Program

Location Restrictions and Program Extensions

Bill: DC B 26-0300 (Law L26-0058) - Effective December 11, 2025, Expires July 24, 2026

District of Columbia enacts temporary amendments extending Streatery Program endorsements and clarifying medical cannabis location restrictions. Published in DC Register Volume 72, Page 013999.

Streatery Program Extension:

• Endorsements continue through December 31, 2025

• Benefits food and beverage businesses with outdoor dining spaces

• Fee payment deadlines: April 1, 2025 (certain licensees) and September 30, 2025 (others)

Marijuana Retailer Location Restrictions:

• New prohibition: 400 feet from educational and recreational facilities

• Exception: Licensees applying prior to Medical Cannabis Clarification and Program Enforcement Amendment Act of 2024 face 300-foot restriction

• Significant compliance impact for cannabis industry location planning

Previous Law Repeal:

• Streatery Program Endorsement Extension Temporary Amendment Act of 2024 repealed

Read DC B 26-0300

NJ Agricultural Support Program

New Jersey Farm Pesticide Collection and Disposal Program

Bill: NJ S 1576 (Passed Senate 37-0 - December 22, 2025)

New Jersey establishes a voluntary farm pesticide, herbicide, and fertilizer collection and disposal program with $1 million appropriation. The bill passed the Senate unanimously and advances to the Assembly.

Program Structure:

• Voluntary participation for commercial farms

• Department of Environmental Protection (DEP) management in collaboration with Department of Agriculture

• Safe collection, transport, and disposal of unused pesticides and fertilizers

• Pesticide container recycling services

Implementation Details:

• Strategically placed collection sites statewide

• Minimum two collection events annually per site

• Local agents appointed to inventory materials and report to DEP

• Public education campaign by Department of Agriculture on collection site locations, accepted materials, and environmental benefits

Objectives:

• Promote environmentally responsible agricultural practices

• Reduce improper pesticide and fertilizer disposal

• Support commercial farming operations with proper waste management resources

Effective Date: 180 days after enactment

Bill Forecast: 95% Assembly floor vote, 63% Assembly passage | 95% Senate floor vote, 75% Senate passage

Read NJ S 1576

Key Compliance Considerations

Hemp Industry Compliance

Wyoming Hemp Licensees:

• Submit renewal documents before December 31, 2025, to extend license expiration to April 15, 2026

• Ensure Criminal History Reports current for all Key Participants

• Implement certified laboratory testing for all batches

• Establish compliant disposal protocols for non-compliant cannabis

New Jersey Hemp & Cannabis Operators:

• Review S 4509 hemp-derived cannabinoid product requirements

• Ensure advertising compliance (no minor targeting)

• Implement comprehensive security protocols

• Update record-keeping systems for regulatory reporting

• License applicants: prepare detailed operating plans with community impact assessments

Alabama Hemp Businesses:

• Monitor SB 1 progress through Senate Committee on Healthcare

• Prepare for potential pharmacy-only distribution model

• Evaluate Alabama-sourced hemp cultivation requirements

• Budget for laboratory testing and certification costs

Cannabis & Marijuana Industry Compliance

Wyoming Hemp Licensees:

• Submit renewal documents before December 31, 2025, to extend license expiration to April 15, 2026

• Ensure Criminal History Reports current for all Key Participants

• Implement certified laboratory testing for all batches

• Establish compliant disposal protocols for non-compliant cannabis

Michigan Cannabis Businesses:

• Prepare for January 1, 2026, retailer and provisioning center license caps

• Calculate municipality population ratios (1 license per 5,000 residents)

• Existing licensees: renewal and transfer provisions do not apply to population caps

• Resort district applicants: prepare tourism-related criteria documentation

New Jersey Hemp & Cannabis Operators:

• Review S 4509 hemp-derived cannabinoid product requirements

• Ensure advertising compliance (no minor targeting)

• Implement comprehensive security protocols

• Update record-keeping systems for regulatory reporting

• License applicants: prepare detailed operating plans with community impact assessments

Florida MMTCs:

• Harvest failure incidents: submit certification documentation within 30 days

• Maintain eight consecutive weeks of active dispensing before wholesale transfer requests

• Update seed-to-sale tracking systems for wholesale transfer documentation

• Budget for potential harvest failure-related costs

Alabama Hemp Businesses:

• Monitor SB 1 progress through Senate Committee on Healthcare

• Prepare for potential pharmacy-only distribution model

• Evaluate Alabama-sourced hemp cultivation requirements

• Budget for laboratory testing and certification costs

Alabama Hemp Businesses:

• Monitor SB 1 progress through Senate Committee on Healthcare

• Prepare for potential pharmacy-only distribution model

• Evaluate Alabama-sourced hemp cultivation requirements

• Budget for laboratory testing and certification costs

Important Policy Deadlines

December 31, 2025:

• Wyoming: 2025 hemp license renewal deadline for April 15, 2026 extension

• District of Columbia: Streatery Program endorsements expire

January 1, 2026:

• Michigan: Marijuana retailer and provisioning center license caps effective

January 13, 2026:

• Alabama: SB 1 first reading and Senate Healthcare Committee referral

July 1, 2026:

• Florida: Veteran medical marijuana registry card fee reduction effective ($15)

July 24, 2026:

• District of Columbia: B 26-0300 temporary amendments expire

Policy Trends & Outlook

Market Access Controls: The trend toward population-based licensing caps in Michigan reflects growing sophistication in cannabis market management. States increasingly balance access expansion with market saturation concerns, particularly in retail sectors.

Federal-State Alignment: New Jersey's hemp-derived cannabinoid framework demonstrates states proactively aligning with federal standards while maintaining robust consumer protection measures. This approach may become a model for other jurisdictions navigating complex hemp product regulation.

Research Expansion: The federal executive order on medical marijuana and CBD research signals potential shifts in federal policy, particularly regarding Schedule III rescheduling. States should monitor federal developments as they may influence state-level cannabis and hemp regulations.

Pharmacy Distribution Models: Alabama's pharmacy-only distribution proposal for hemp products represents a conservative regulatory approach prioritizing traditional healthcare distribution channels. While unlikely to become widespread, this model illustrates the diversity of state approaches to hemp product safety.

Agricultural Support Integration: New Jersey's pesticide collection program demonstrates states supporting sustainable agricultural practices across all sectors, including emerging hemp and cannabis cultivation operations.

AHAA Action Items

For Hemp Businesses:

• Wyoming licensees: submit renewal documentation before December 31, 2025

• New Jersey operators: audit operations for S 4509 hemp product framework compliance

• Alabama businesses: monitor SB 1 pharmacy distribution model legislation

• All hemp businesses: verify product testing certificates and laboratory compliance

• Prepare for increased operational costs related to testing and compliance requirements

For Cannabis & Marijuana Businesses:

• Michigan retailers: analyze municipality population ratios for license cap compliance

• Florida MMTCs: review harvest failure protocols and wholesale transfer procedures

• New Jersey operators: engage with S 4847 Cannabis Regulatory Commission reform

• Ohio licensees: monitor SB 56 implementation and governor action

• All cannabis businesses: prepare for Division of Cannabis Control oversight requirements

For Healthcare Providers:

• Review expanded qualifying conditions (New Jersey sickle cell anemia)

• Understand Florida veteran fee reduction eligibility and documentation requirements

• Monitor federal research initiatives and potential Schedule III rescheduling impacts

• Update patient education materials regarding program changes

For Patients & Consumers:

• New Jersey sickle cell anemia patients: explore medical cannabis program eligibility

• Florida veterans: prepare documentation for $15 registry card fee (effective July 1, 2026)

• All consumers: verify product testing certificates and laboratory compliance

• Stay informed on state-specific location restrictions and access points

For Industry Advocates:

• Engage with Alabama SB 1 Senate Healthcare Committee review process (hemp)

• Monitor Michigan retailer license cap implementation for market impact (cannabis)

• Support New Jersey S 4847 Cannabis Regulatory Commission reform efforts (cannabis)

• Advocate for federal Schedule III rescheduling and research expansion (both markets)

• Participate in state regulatory comment periods as announced (both markets)

• Support evidence-based hemp product safety standards

• Promote equitable cannabis licensing frameworks

Conclusion

The week of December 29, 2025, marks a significant transition period as states finalize year-end regulations and prepare for 2026 implementation deadlines. Wyoming's comprehensive hemp framework establishes clear production standards, Michigan introduces sophisticated market controls through population-based licensing caps, and New Jersey advances federal-aligned hemp product regulation while reforming its Cannabis Regulatory Commission structure.

The federal executive order on medical marijuana research represents a pivotal moment in national cannabis policy, supporting Schedule III rescheduling and emphasizing evidence-based approaches to cannabinoid medicine. This federal momentum, combined with state-level regulatory maturation, positions 2026 as a transformative year for cannabis and hemp policy nationwide.

Florida's harvest failure protocols demonstrate regulatory recognition of agricultural realities facing cannabis cultivators, while New Jersey's addition of sickle cell anemia to qualifying conditions and veteran fee reductions reflect patient-centered program expansion. Alabama's pharmacy-only distribution proposal illustrates ongoing debates about appropriate hemp product retail channels and consumer safety frameworks.

AHAA continues monitoring these developments and advocating for science-based, equitable cannabis and hemp policies that prioritize consumer safety, industry sustainability, and patient access. As regulatory frameworks mature across jurisdictions, industry stakeholders must remain vigilant regarding compliance requirements and emerging best practices.

Take Action With AHAA

Make Your Voice Heard

Cannabis and hemp policy affects patients, businesses, and communities nationwide. AHAA's Action Center empowers you to engage directly with policymakers on legislation that matters to you.

Visit AHAA Action Center to:

• Contact your representatives about pending bills

• Submit public comments on regulations

• Stay informed on legislative developments

• Join advocacy campaigns

Join the AHAA Movement

Support evidence-based cannabis and hemp policy reform by becoming an AHAA member. Your membership fuels our advocacy efforts, policy research, and educational initiatives.

Explore AHAA Membership Options

Member benefits include:

• Weekly policy reports and analysis

• Exclusive industry insights

• Advocacy training and resources

• Direct access to policy experts

• Discounts on AHAA events and products

Together, we're building a better future for cannabis and hemp policy.

This report was compiled by the American Health Alternatives Association (AHAA) team. For questions or additional information, please contact us.